Global Bladder Cancer Therapeutics Market to Reach $345.3 Million by 2030
The global market for Bladder Cancer Therapeutics estimated at US$244.4 Million in the year 2022, is projected to reach a revised size of US$345.3 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. Transitional Cell Bladder Cancer, one of the segments analyzed in the report, is projected to record a 3.9% CAGR and reach US$114.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non Muscle Invasive / Superficial Bladder Cancer segment is readjusted to a revised 5.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $66.6 Million, While China is Forecast to Grow at 7.3% CAGR
The Bladder Cancer Therapeutics market in the U.S. is estimated at US$66.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$72.2 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 3.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$46.5 Million by the year 2030.Select Competitors (Total 62 Featured) -
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 283 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 244.4 Million |
Forecasted Market Value ( USD | $ 345.3 Million |
Compound Annual Growth Rate | 4.4% |
Regions Covered | Global |